ATRC

AtriCure develops and manufactures medical devices treating cardiac arrhythmias, particularly atrial fibrillation, through surgical ablation systems, cardiac occlusion devices, and related products serving cardiac surgeons and electrophysiologists worldwide. Headquartered in Mason, Ohio, AtriCure pioneered radiofrequency ablation systems enabling surgeons to create lesion patterns isolating irregular electrical signals causing atrial fibrillation during open-heart and minimally invasive cardiac procedures. The company's product portfolio includes AtriClip left atrial appendage exclusion devices preventing stroke risk in atrial fibrillation patients by mechanically closing the heart structure where blood clots commonly form, Isolator surgical ablation systems for concomitant atrial fibrillation treatment during cardiac surgeries, and EPi-Sense guided coagulation systems for minimally invasive stand-alone atrial fibrillation procedures. AtriCure generates approximately 60% of revenues in the United States with international sales contributing 40%, selling through direct sales representatives in major markets and distribution partners in smaller regions. The company reported annual revenues exceeding $350 million with strong growth rates of 15-20% driven by increasing atrial fibrillation prevalence affecting over 6 million Americans, expanding indications for surgical ablation during cardiac procedures, and growing adoption of minimally invasive approaches reducing procedural risks and recovery times. AtriCure completed numerous clinical trials demonstrating safety and efficacy including the landmark aMAZE trial showing superior atrial fibrillation treatment outcomes combining surgical ablation with standard cardiac surgeries compared to surgery alone. The company faces competition from electrophysiology catheter ablation systems from Biosense Webster, Medtronic, and Abbott offering less-invasive alternatives for certain patient populations, plus left atrial appendage occlusion devices from Boston Scientific and Abbott. Recent strategic priorities include expanding indications for AtriClip beyond surgical patients to percutaneous deployment potentially reaching broader patient populations, advancing clinical evidence supporting reimbursement coverage for stand-alone surgical ablation procedures, and developing next-generation energy sources improving ablation efficacy and procedural efficiency.